Vessi Medical, a provider of cryotherapy technology to treat non-muscle invasive bladder cancer (NMIBC), announced it has closed a $16.5 million Series A funding round.
The company offers: A cryospray for hollow, humid organs, it is being touted as a new treatment approach for NMIBC, a cancer found on the surface of the inner wall of the bladder.
The Israeli company says its cryotherapy offering is a minimally invasive alternative to transurethral bladder tumor resection, a first-line surgical treatment in which surgeons remove a patient's bladder tumor through the urethra. ing.
ALIVE – Israel HealthTech Fund, Agriline, and undisclosed strategic investors led the Series A investment round.
“We are excited to announce the closing of this round, especially during these difficult times,” Eyal Kochavi, founder and CEO of Vessi Medical, said in a statement.
“The participation of global strategic investors in this round is a sign of great confidence in Vessi’s performance and potential. Our goal is to support clinical research, regulatory clearance, and enable us to achieve Vessi's commitment to NMIBC to reduce side effects, improve patient outcomes, and reduce healthcare costs. It's about providing treatments to patients and doctors. ”
Merit Medicine, a company that provides AI technology to companies that self-fund employee health insurance, announced it has closed a $2 million seed round led by LiveOak Ventures.
Merit leverages AI to help self-funded employers anticipate budgeting needs based on patient visit datasets, helping employers identify potential high medical costs, scarcity, We help you gain insight into the use of specialty medications for chronic, complex conditions.
“Self-financed employers face increased healthcare costs and significant financial risks based on the health status of their employees,” Mike Marcantonio, head of investments at Live Oak Ventures, said in a statement. . “Unfortunately, there are currently few tools to assess and plan for this risk.”
“When I met the Merit Medicine team, I realized their commitment to helping employers address this risk by using AI to predict the use of expensive specialty medicines and rare, chronic, and complex conditions. Inspired by our mission, our team's domain experience also stands out with experience in: drug pricing, market access, and healthcare data analytics.”
